Supplementary TABLE: Serious Adverse Events (SAE) by Allocation*

	Enteral Levetiracetam (n=23)	**Usual Care (n=21) Phenobarbital Intent-to-Treat**	**Phenobarbital received per protocol (n=15)**
Any SAE	5 (22%)	8 (38%)	8 (53%)
Thrombocytopenia^	2 (9%)	1 (5%)	1 (7%)
Elevated AST	3 (13%)	2 (10%)	2 (13%)
Acute kidney injury	1 (4%)	0	0
Respiratory suppression/aspiration	**0**	**4 (19%)**	**4 (27%)**
Death	1 (4%)	5 (24%)	5 (33%)

* All comparisons p>0.05. SADRs are noted in **bold**

^ 50% decrease from baseline at 24 hours post randomization or <25,000 per µL at 7 days post randomization